|
NAPB expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.44169137633799E-15 |
| Normal-vs-Stage2 |
8.44929999965771E-07 |
| Normal-vs-Stage3 |
4.44089209850063E-16 |
| Normal-vs-Stage4 |
2.77766698530968E-12 |
| Stage1-vs-Stage2 |
2.026400E-01 |
| Stage1-vs-Stage3 |
1.341940E-02 |
| Stage1-vs-Stage4 |
2.400300E-02 |
| Stage2-vs-Stage3 |
6.542300E-03 |
| Stage2-vs-Stage4 |
9.284500E-03 |
| Stage3-vs-Stage4 |
7.330200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.22899999999149E-06 |
| Normal-vs-Asian |
5.95490001753518E-09 |
| Caucasian-vs-AfricanAmerican |
5.323000E-01 |
| Caucasian-vs-Asian |
1.107450E-01 |
| AfricanAmerican-vs-Asian |
6.140000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.71844785465692E-14 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
6.446600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62792002100787E-12 |
| Normal-vs-Age(41-60Yrs) |
2.35367281220533E-14 |
| Normal-vs-Age(61-80Yrs) |
2.64943622596547E-12 |
| Normal-vs-Age(81-100Yrs) |
2.18369999999135E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.338600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.119600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.302800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.446800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.118200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.261600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.15649999998801E-06 |
| Classical-VS-Follicular |
4.737900E-03 |
| Classical-VS-Other |
8.087800E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
4.2290999591188E-09 |
| Tall-VS-Other |
5.923000E-03 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
4.731000E-01 |
| Follicular-VS-Normal |
1.82465999999382E-05 |
| Other-VS-Normal |
3.195300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.70783395706076E-13 |
| Normal-vs-N1 |
2.54550047706914E-10 |
| N0-vs-N1 |
1.466580E-01 |
|
|
